Alcon's annual operating income falls 16%
Operating income for Alcon in 2013 was $1.2 billion, a decline of 16% over the previous year, according to a press release from Novartis.
The decline was attributed to integration and restructuring costs and was partially offset by sales growth — 3% over the previous year — and productivity gains.
The Alcon surgical franchise increased by 4% in 2013 over 2012. This was driven by procedure growth, market share gains and demand for LenSx and Centurion equipment.
Ophthalmic pharmaceuticals grew 2% in 2013 due to market share gains across key segments, but generic competition affected the U.S. glaucoma segment.
Vision care experienced 2% growth.
Novartis reported a net income of $9.29 billion for 2013, representing a 1% decline over 2012.
Net income for the fourth quarter was $2.06 billion, a 2% increase over $2.02 billion reported in the fourth quarter of 2012.